Literature DB >> 11356104

Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.

Y Pak1, I J Enyedy, J Varady, J W Kung, P S Lorenzo, P M Blumberg, S Wang.   

Abstract

The structural basis of protein kinase C (PKC) binding to several classes of high-affinity ligands has been investigated through complementary computational and experimental methods. Employing a recently developed q-jumping molecular dynamics (MD) simulation method, which allows us to consider the flexibility of both the ligands and the receptor in docking studies, we predicted the binding models of phorbol-13-acetate, phorbol-12,13-dibutyrate (PDBu), indolactam V (ILV), ingenol-3-benzoate, and thymeleatoxin to PKC. The "predicted" binding model for phorbol-13-acetate is virtually identical to the experimentally determined binding model for this ligand. The predicted binding model for PDBU is the same as that for phorbol-13-acetate in terms of the hydrogen-bonding network and hydrophobic contacts. The predicted binding model for ILV is the same as that obtained in a previous docking study using a Monte Carlo method and is consistent with the structure-activity relationships for this class of ligands. Together with the X-ray structure of phorbol-13-acetate in complex with PKCdelta C1b, the predicted binding models of PDBu, ILV, ingenol-3-benzoate, and thymeleatoxin in complex with PKC showed that the binding of these ligands to PKC is governed by a combination of several highly specific and optimal hydrogen bonds and hydrophobic contacts. However, the hydrogen-bonding network for each class of ligand is somewhat different and the number of hydrogen bonds formed between PKC and these ligands has no correlation with their binding affinities. To provide a direct and quantitative assessment of the contributions of several conserved residues around the binding site to PKC-ligand binding, we have made 11 mutations and measured the binding affinities of the high-affinity PKC ligands to these mutants. The results obtained through site-directed mutagenic analysis support our predicted binding models for these ligands and provide new insights into PKC-ligand binding. Although all the ligands have high affinity for the wild-type PKCdelta C1b, our site-directed mutagenic results showed that ILV is the ligand most sensitive to structural perturbations of the binding site while ingenol-3-benzoate is the least sensitive among the four classes of ligands examined here. Finally, we have employed conventional MD simulations to investigate the structural perturbations caused by each mutation to further examine the role played by each individual residue in PKC-ligand binding. MD simulations revealed that several mutations, including Pro11 --> Gly, Leu21 --> Gly, Leu24 --> Gly, and Gln27 --> Gly, cause a rather large conformational alteration to the PKC binding site and, in some cases, to the overall structure of the protein. The complete abolishment or the significant reduction in PKC-ligand binding observed for these mutants thus reflects the loss of certain direct contacts between the side chain of the mutated residue in PKC and ligands as well as the large conformational alteration to the binding site caused by the mutation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11356104     DOI: 10.1021/jm000488e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  Some phorbol esters might partially resemble bryostatin 1 in their actions on LNCaP prostate cancer cells and U937 leukemia cells.

Authors:  Noemi Kedei; Emanuel Lubart; Nancy E Lewin; Andrea Telek; Langston Lim; Poonam Mannan; Susan H Garfield; Matthew B Kraft; Gary E Keck; Sofiya Kolusheva; Raz Jelinek; Peter M Blumberg
Journal:  Chembiochem       Date:  2011-05-03       Impact factor: 3.164

2.  Inhibition of protein kinase C catalytic activity by additional regions within the human protein kinase Calpha-regulatory domain lying outside of the pseudosubstrate sequence.

Authors:  Angie F Kirwan; Ashley C Bibby; Thierry Mvilongo; Heimo Riedel; Thomas Burke; Sherri Z Millis; Amadeo M Parissenti
Journal:  Biochem J       Date:  2003-07-15       Impact factor: 3.857

3.  Molecular basis for failure of "atypical" C1 domain of Vav1 to bind diacylglycerol/phorbol ester.

Authors:  Tamas Geczy; Megan L Peach; Saïd El Kazzouli; Dina M Sigano; Ji-Hye Kang; Christopher J Valle; Julia Selezneva; Wonhee Woo; Noemi Kedei; Nancy E Lewin; Susan H Garfield; Langston Lim; Poonam Mannan; Victor E Marquez; Peter M Blumberg
Journal:  J Biol Chem       Date:  2012-02-18       Impact factor: 5.157

4.  Charge density influences C1 domain ligand affinity and membrane interactions.

Authors:  Jessica S Kelsey; Tamas Geczy; Nancy E Lewin; Noemi Kedei; Colin S Hill; Julia S Selezneva; Christopher J Valle; Wonhee Woo; Inna Gorshkova; Peter M Blumberg
Journal:  Chembiochem       Date:  2014-04-28       Impact factor: 3.164

5.  Identification of the activator-binding residues in the second cysteine-rich regulatory domain of protein kinase Cθ (PKCθ).

Authors:  Ghazi M Rahman; Sreejesh Shanker; Nancy E Lewin; Noemi Kedei; Colin S Hill; B V Venkataram Prasad; Peter M Blumberg; Joydip Das
Journal:  Biochem J       Date:  2013-04-01       Impact factor: 3.857

Review 6.  Dynamics and Membrane Interactions of Protein Kinase C.

Authors:  Tatyana I Igumenova
Journal:  Biochemistry       Date:  2015-08-05       Impact factor: 3.162

Review 7.  Wealth of opportunity - the C1 domain as a target for drug development.

Authors:  P M Blumberg; N Kedei; N E Lewin; D Yang; G Czifra; Y Pu; M L Peach; V E Marquez
Journal:  Curr Drug Targets       Date:  2008-08       Impact factor: 3.465

Review 8.  Structural insights into C1-ligand interactions: Filling the gaps by in silico methods.

Authors:  Sachin Katti; Tatyana I Igumenova
Journal:  Adv Biol Regul       Date:  2021-01-18

9.  Combining docking with pharmacophore filtering for improved virtual screening.

Authors:  Megan L Peach; Marc C Nicklaus
Journal:  J Cheminform       Date:  2009-05-20       Impact factor: 5.514

10.  RasGRPs are targets of the anti-cancer agent ingenol-3-angelate.

Authors:  Xiaohua Song; Ana Lopez-Campistrous; Lucy Sun; Nancy A Dower; Noemi Kedei; Jing Yang; Jessica S Kelsey; Nancy E Lewin; Tim E Esch; Peter M Blumberg; James C Stone
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.